DE60125529D1 - MIKROORGANISMEN FüR DIE BEHANDLUNG ODER VORBEUGUNG VON FETTLEIBIGKEIT UND DIABETES MELLITUS UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN - Google Patents

MIKROORGANISMEN FüR DIE BEHANDLUNG ODER VORBEUGUNG VON FETTLEIBIGKEIT UND DIABETES MELLITUS UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN

Info

Publication number
DE60125529D1
DE60125529D1 DE60125529T DE60125529T DE60125529D1 DE 60125529 D1 DE60125529 D1 DE 60125529D1 DE 60125529 T DE60125529 T DE 60125529T DE 60125529 T DE60125529 T DE 60125529T DE 60125529 D1 DE60125529 D1 DE 60125529D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
diabetes mellitus
fatibility
organisms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60125529T
Other languages
English (en)
Other versions
DE60125529T2 (de
Inventor
Han-Oh Park
Hea-Jung Joung
Bong-Cheol Kim
Hang-Rae Kim
Young-Bae Bang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioneer Corp
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2000-0049805A external-priority patent/KR100404236B1/ko
Application filed by Bioneer Corp filed Critical Bioneer Corp
Application granted granted Critical
Publication of DE60125529D1 publication Critical patent/DE60125529D1/de
Publication of DE60125529T2 publication Critical patent/DE60125529T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/02—Acetobacter
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/823—Acetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60125529T 2000-05-17 2001-02-23 MIKROORGANISMEN FüR DIE BEHANDLUNG ODER VORBEUGUNG VON FETTLEIBIGKEIT UND DIABETES MELLITUS UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN Expired - Lifetime DE60125529T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20000026379 2000-05-17
KR2000026379 2000-05-17
KR10-2000-0049805A KR100404236B1 (ko) 2000-05-17 2000-08-26 비만 또는 당뇨병 치료용 미생물 및 상기 미생물을포함하는 의약 조성물
KR2000049805 2000-08-26
PCT/KR2001/000269 WO2001088095A1 (en) 2000-05-17 2001-02-23 Microorganisms for treatment or prevention of obesity and diabetes mellitus, and pharmaceutical composition containing the same

Publications (2)

Publication Number Publication Date
DE60125529D1 true DE60125529D1 (de) 2007-02-08
DE60125529T2 DE60125529T2 (de) 2007-10-04

Family

ID=26637996

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60125529T Expired - Lifetime DE60125529T2 (de) 2000-05-17 2001-02-23 MIKROORGANISMEN FüR DIE BEHANDLUNG ODER VORBEUGUNG VON FETTLEIBIGKEIT UND DIABETES MELLITUS UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN

Country Status (8)

Country Link
US (4) US6808703B2 (de)
EP (1) EP1282687B1 (de)
JP (1) JP4580542B2 (de)
CN (1) CN1380902B (de)
AT (1) ATE349511T1 (de)
AU (1) AU3617001A (de)
DE (1) DE60125529T2 (de)
WO (1) WO2001088095A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431108A1 (en) * 2000-12-21 2002-06-27 Societe Des Produits Nestle S.A. Lactobacillus strain producing levan and its use in human or pet food products
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
US20060100171A1 (en) * 2002-09-09 2006-05-11 Ekhart Peter F Branched alpha-glucans for weight management
CA2517245C (en) 2003-02-28 2009-01-20 Mcgill University Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
WO2006084381A1 (en) * 2005-02-11 2006-08-17 Technologie Biolactis Inc. Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic
KR20110095929A (ko) * 2005-07-26 2011-08-25 네스텍 에스.아. 항비만제 및 항비만 식품
SE529185C2 (sv) 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
EP1983849B1 (de) * 2006-01-20 2013-04-03 Innova Food AB Aminosäurehaltige nahrungsmittelzusammensetzung
ES2693584T3 (es) * 2006-01-27 2018-12-12 Dupont Nutrition Biosciences Aps Uso de microorganismos probióticos para el tratamiento y prevención de obesidad y trastornos relacionados
KR101108428B1 (ko) 2006-08-04 2012-01-31 (주)바이오니아 인간의 모유에서 분리한 프로바이오틱 활성 및 체중 증가억제 효과를 갖는 유산균
JP5089942B2 (ja) * 2006-09-04 2012-12-05 雪印メグミルク株式会社 内臓脂肪蓄積抑制剤
CN101678051B (zh) * 2006-09-04 2012-12-12 雪印惠乳业株式会社 促进血中脂连蛋白浓度增加及/或抑制其减少的制剂及内脏脂肪蓄积抑制剂
EP2073643A2 (de) * 2006-10-18 2009-07-01 DSMIP Assets B.V. Verkapselung von hitze- und feuchtigkeitsempfindlichen substanzen
EP1987726A1 (de) * 2007-05-01 2008-11-05 Friesland Brands B.V. Wohlschmeckendes Nahrungsmittel mit Neutralisierungsmittel für Verbindungen mit Nebenwirkungen
EP2011506A1 (de) 2007-07-05 2009-01-07 Nestec S.A. Ergänzung zu einer Schwangerschaftsdiät
JP2009114163A (ja) * 2007-11-05 2009-05-28 Nippon Energy Kenkyusho:Kk 複合微生物の培養生成物を有効成分とする血糖降下剤および血糖降下機能食品
WO2009066681A1 (ja) * 2007-11-19 2009-05-28 Kaneka Corporation 乳酸菌含有製剤
EP2065048A1 (de) * 2007-11-30 2009-06-03 Institut Pasteur Verwendung eines L.-casei-Stammes zur Herstellung einer Zusammensetzung zur Mastzellenaktivierung
PL2262514T3 (pl) * 2008-03-07 2020-06-15 Savencia Sa Środki do wspomagania wydzielania i/lub hamowania spadku adiponektyny
ES2390620T3 (es) 2008-03-10 2012-11-14 Nestec S.A. Ácidos dicarboxílicos de cadena mediana y sus derivados y trastornos metabólicos
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
US9474773B2 (en) 2009-02-18 2016-10-25 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
JP5569710B2 (ja) * 2009-02-27 2014-08-13 国立大学法人広島大学 肥満予防又は改善剤
JP5665196B2 (ja) * 2009-03-10 2015-02-04 ジニス バイオファーマサティカルズ カンパニーＪｉｎｉｓ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ． 微生物を利用した肥満及び肥満によって引き起こされた代謝性疾患の予防と治療
EP2442814B1 (de) * 2009-06-19 2018-09-26 DuPont Nutrition Biosciences ApS Bifidobakterien zur behandlung der diabetes und verwandten krankheiten
CN101703528B (zh) * 2009-11-25 2012-07-04 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用
CN102935092B (zh) * 2010-06-09 2014-03-26 景岳生物科技股份有限公司 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
KR101234582B1 (ko) * 2011-04-22 2013-02-19 전남대학교산학협력단 알파 글루코시다제 활성 저해용 조성물
KR101228035B1 (ko) * 2011-06-29 2013-01-30 주식회사 쎌바이오텍 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물
CN102533588B (zh) * 2011-12-06 2013-12-11 光明乳业股份有限公司 一株产胞外多糖的短乳杆菌及其应用
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
JP5967527B2 (ja) * 2012-06-22 2016-08-10 国立研究開発法人産業技術総合研究所 食欲増進かつ体重増加抑制剤
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
CN104968780A (zh) * 2012-09-20 2015-10-07 普洛特拉有限公司 用于治疗肥胖和肥胖相关病症的益生菌组合物和方法
CA2908032A1 (en) 2013-04-17 2014-10-23 Suntory Holdings Limited Composition containing bacterium belonging to genus lactobacillus
CN103275905B (zh) * 2013-05-31 2014-12-10 江南大学 具有预防糖尿病作用的鼠李糖乳杆菌ccfm0528
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
US20160271189A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
US20160353774A1 (en) * 2015-06-02 2016-12-08 Mead Johnson Nutrition Company Nutritional compositions comprising spore-forming probiotics
JP6858751B2 (ja) 2015-08-20 2021-04-14 アセコー インコーポレイテッド 糖尿病管理療法アドバイザ
CN107028985A (zh) * 2016-02-04 2017-08-11 深圳华大基因研究院 厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
CN108778292B (zh) * 2016-02-24 2022-05-03 内斯托尔株式会社 包含肠膜明串珠菌产生的外泌多糖作为活性成分的用于预防或治疗代谢障碍的组合物
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
MY197201A (en) 2017-02-10 2023-05-31 Perfect China Co Ltd Novel probiotics bifidobacteria strains
US11389487B2 (en) 2017-08-06 2022-07-19 Second Genome, Inc. Streptococcus australis as a biotherapeutic
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
US11344584B2 (en) 2017-09-26 2022-05-31 Second Genome, Inc. Gemella sanguinis as a biotherapeutic
TWI710321B (zh) * 2018-05-03 2020-11-21 綠茵生技股份有限公司 低糖蔬果酵素液之製作方法
JP7219026B2 (ja) * 2018-07-11 2023-02-07 雪印メグミルク株式会社 食後血糖値上昇抑制用組成物及びその製造方法
JP7267020B2 (ja) * 2019-01-24 2023-05-01 株式会社明治 血糖値上昇抑制作用を有する発酵乳
SG11202109231WA (en) * 2019-02-26 2021-09-29 Univ Nat Chonnam Ind Found Composition comprising lactobacillus sakei cvl-001 or culture liquid thereof for alleviating, preventing, or treating bone diseases or metabolic diseases
CN110144311B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN110184214B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN111587952A (zh) * 2020-05-27 2020-08-28 佛山科学技术学院 一种降低家犬体脂沉积的益生菌添加剂
CN111661933B (zh) * 2020-06-30 2022-08-16 武汉合缘绿色生物股份有限公司 一种用于调节水体营养及预防病害的生物制剂及其制备方法
CN113512520B (zh) * 2021-04-29 2022-04-26 右江民族医学院 富铬富锌醋酸杆菌及其制备方法和应用
EP4183403A1 (de) * 2021-11-19 2023-05-24 Lietuvos Sveikatos Mokslu Universitetas Modifikation von fäkalen mikrobiota mit kapseln, die gram-positive bakterien enthalten
CN116121154B (zh) * 2023-04-10 2023-06-27 四川厌氧生物科技有限责任公司 一种乳明串珠菌及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0075604A1 (de) * 1981-09-24 1983-04-06 Asahi Kasei Kogyo Kabushiki Kaisha Mittel zur Senkung des Blutzuckerspiegels
US4568557A (en) * 1983-05-11 1986-02-04 Warner-Lambert Company Process for producing snack food product with high dietary fiber content
JPS615019A (ja) * 1984-06-18 1986-01-10 Nakano Vinegar Co Ltd 血糖低下剤
EP0194794A3 (de) * 1985-03-08 1986-12-17 Takeda Chemical Industries, Ltd. Saccharid-Verdauung hemmende Zusammensetzung
US5527772A (en) * 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
JP2928335B2 (ja) * 1989-06-26 1999-08-03 株式会社ヤクルト本社 抗高血圧剤および飲食品
JP2939491B2 (ja) * 1989-12-11 1999-08-25 株式会社アドバンス 機能性食品
JPH0735339B2 (ja) * 1991-09-09 1995-04-19 雪印乳業株式会社 血清コレステロール上昇抑制剤及び飲食品
JP3202053B2 (ja) * 1992-01-09 2001-08-27 カネボウ株式会社 腸溶性造粒物
JP3187502B2 (ja) * 1992-01-09 2001-07-11 カネボウ株式会社 腸溶性造粒物
CA2127392C (en) * 1993-07-08 2008-05-27 Hideki Sunohara Process for producing capsule and capsule obtained thereby
JPH107577A (ja) * 1996-06-17 1998-01-13 Yakult Honsha Co Ltd 血糖降下剤
ATE314858T1 (de) * 1998-04-01 2006-02-15 Ganeden Biotech Inc Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen
EP0956867A1 (de) * 1998-05-12 1999-11-17 Franz-Peter Dr. Liebel Verwendung von Flavonoidglykosiden, Gerbstoffen und Mikroorganismen zur Therapie und Prophylaxe des Diabetes mellitus
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6464607B1 (en) * 1999-12-15 2002-10-15 The Goodyear Tire & Rubber Company Power transmission belt
US6486314B1 (en) * 2000-05-25 2002-11-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Glucan incorporating 4-, 6-, and 4, 6- linked anhydroglucose units
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus

Also Published As

Publication number Publication date
US20020037577A1 (en) 2002-03-28
EP1282687A1 (de) 2003-02-12
EP1282687B1 (de) 2006-12-27
CN1380902A (zh) 2002-11-20
CN1380902B (zh) 2010-10-27
DE60125529T2 (de) 2007-10-04
US20030180273A1 (en) 2003-09-25
AU3617001A (en) 2001-11-26
WO2001088095A1 (en) 2001-11-22
ATE349511T1 (de) 2007-01-15
JP2001321163A (ja) 2001-11-20
US20030180271A1 (en) 2003-09-25
US6808703B2 (en) 2004-10-26
US20050112112A1 (en) 2005-05-26
JP4580542B2 (ja) 2010-11-17

Similar Documents

Publication Publication Date Title
DE60125529D1 (de) MIKROORGANISMEN FüR DIE BEHANDLUNG ODER VORBEUGUNG VON FETTLEIBIGKEIT UND DIABETES MELLITUS UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN
MA33046B1 (fr) Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp- iv et facultativemenet un autre agent antidiabetique et ses utilisations
Katsura et al. In vitro antimicrobial activities of bakuchiol against oral microorganisms
BR0112685A (pt) Composição nutricional
BR0109326A (pt) Inibidores de sglt2 de glucosìdio de o-arila e método
SG170119A1 (en) Nutritional composition comprising indigestible oligosaccharides
MX2010001560A (es) Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv.
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
IL107134A0 (en) Pharmaceutical compositions for the treatment of parkinson's disease
TN2009000177A1 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
BR0114310A (pt) Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
DE69739415D1 (de) Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten
WO2006032500A3 (en) Immunogenic composition
PL348097A1 (en) Application of biochemical substances in compositions for preventing occurrence and treating pathogenous states caused by muscular contraction of smooth muscles in body organs
WO2006023342A3 (en) Synergistic conjugated linoleic acid (cla) and carnitine combination
PT1254146E (pt) Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
EP2392322A3 (de) Dosierschemata für Trans-Clomiphen
PT1455802E (pt) Oligossacáridos de quitosano e suas utilizações
WO2004004636A3 (en) Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
BR0314335A (pt) Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
BR0112919A (pt) Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter
GB2456475A (en) Composition for the treatment of skin conditions
TW200724147A (en) Cognitive abilities improving agent
SE9901007D0 (sv) Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
BR0311463A (pt) Composições compreendendo uma bactéria do gênero dietzia que são úteis para o tratamento de paratuberculose em ruminantes e método para a cultura da bactéria

Legal Events

Date Code Title Description
8364 No opposition during term of opposition